Home | The Incretin Space

The Incretin Space

A collection of collated data on incretin drug developments, including new drugs, new treatments and the future of incretins in medicine

Written by

The Incretin Space

Most Recent

Reversing 50 years of glucagon dogma in one summer

Oct 26, 2026

Reversing 50 years of glucagon dogma in one summer

Rewriting the textbook on glucagon and insulin sensitivity

Surv-ing up Diabetes

Oct 12, 2026

Surv-ing up Diabetes

Survodutide syncs a type 2 diabetes win with caveats

Clearing the CVOT hurdle

Oct 7, 2026

Clearing the CVOT hurdle

Not ‘kidneying’ around about orforglipron’s potential benefits

EASD 2026: The weight equation is solved?

Oct 5, 2026

EASD 2026: The weight equation is solved?

Retatrutide and EloraTirz provide shock and awe at EASD

Advancing Insulin Sensitivity Training

Sep 29, 2026

Advancing Insulin Sensitivity Training

Or how tirzepatide became king and GIP is why

Brenipatide, VK2735 and Enicepatide

Sep 24, 2026

Brenipatide, VK2735 and Enicepatide

All hail the current and future GIP kings

(Insulin) Sensitivity Training

Sep 14, 2026

(Insulin) Sensitivity Training

An intro guide to a misunderstood metric of diabetic and cardiometabolic risk

The Clue is in Ketones

Aug 31, 2026

The Clue is in Ketones

Retatrutide's metabolomics data reveals hints about weight loss differences between diabetics and non-diabetics

Archive

Survodutide

+2

Reversing 50 years of glucagon dogma in one summer

Oct 26, 2026

•

10 min read

Reversing 50 years of glucagon dogma in one summer

Rewriting the textbook on glucagon and insulin sensitivity

Surv-ing up Diabetes

Oct 12, 2026

•

5 min read

Surv-ing up Diabetes

Survodutide syncs a type 2 diabetes win with caveats

Tirzepatide

+1

Clearing the CVOT hurdle

Oct 7, 2026

•

6 min read

Clearing the CVOT hurdle

Not ‘kidneying’ around about orforglipron’s potential benefits

GLP-1

+5

EASD 2026: The weight equation is solved?

Oct 5, 2026

•

16 min read

EASD 2026: The weight equation is solved?

Retatrutide and EloraTirz provide shock and awe at EASD

Tirzepatide

+1

Advancing Insulin Sensitivity Training

Sep 29, 2026

•

10 min read

Advancing Insulin Sensitivity Training

Or how tirzepatide became king and GIP is why

Brenipatide, VK2735 and Enicepatide

Sep 24, 2026

•

11 min read

Brenipatide, VK2735 and Enicepatide

All hail the current and future GIP kings

GLP-1

+2

(Insulin) Sensitivity Training

Sep 14, 2026

•

15 min read

(Insulin) Sensitivity Training

An intro guide to a misunderstood metric of diabetic and cardiometabolic risk

Glucagon

+2

The Clue is in Ketones

Aug 31, 2026

•

10 min read

The Clue is in Ketones

Retatrutide's metabolomics data reveals hints about weight loss differences between diabetics and non-diabetics

GLP-1

+3

Retatrutide revolution continues

Jul 28, 2026

•

7 min read

Retatrutide revolution continues

Weight loss remains the star of the show, but cardiovascular data was underpowered